BACKGROUND AND OBJECTIVES: Fas ligand (FasL) is expressed in many cancers and plays an important role in establishing immunologically privileged environments that allow tumors to escape the host's immune surveillance. We investigate the expression of FasL in human colorectal cancer and colorectal adenoma and elucidate the relationship between FasL expression and the clinicopathological characteristics of colorectal cancers. METHODS: We examined 214 colorectal cancer specimens and 83 colorectal adenoma specimens. Expression of FasL was determined by immunohistochemical staining using a specific monoclonal antibody. We analyzed the relationship between the results of FasL expression and clinicopathological data statistically. RESULTS: FasL expression was detected in 173 (80.8%) of 214 colorectal carcinomas and 34 (40.9%) of 83 colorectal adenomas. The status of FasL expression in colorectal carcinoma was independent of clinicopathological features including tumor stage, histologic grade, lymphatic invasion, venous invasion, lymph node metastasis, liver metastasis, and Dukes stage. In colorectal adenoma, FasL expression was more frequently observed in high-grade atypia than in low-grade atypia (P = 0.05). CONCLUSIONS: FasL expression is commonly observed not only in cancer but also in highly dysplastic tissue. These observations suggest that FasL expression may be an important event in the transformation process leading to adenocarcinoma.
BACKGROUND AND OBJECTIVES:Fas ligand (FasL) is expressed in many cancers and plays an important role in establishing immunologically privileged environments that allow tumors to escape the host's immune surveillance. We investigate the expression of FasL in humancolorectal cancer and colorectal adenoma and elucidate the relationship between FasL expression and the clinicopathological characteristics of colorectal cancers. METHODS: We examined 214 colorectal cancer specimens and 83 colorectal adenoma specimens. Expression of FasL was determined by immunohistochemical staining using a specific monoclonal antibody. We analyzed the relationship between the results of FasL expression and clinicopathological data statistically. RESULTS:FasL expression was detected in 173 (80.8%) of 214 colorectal carcinomas and 34 (40.9%) of 83 colorectal adenomas. The status of FasL expression in colorectal carcinoma was independent of clinicopathological features including tumor stage, histologic grade, lymphatic invasion, venous invasion, lymph node metastasis, liver metastasis, and Dukes stage. In colorectal adenoma, FasL expression was more frequently observed in high-grade atypia than in low-grade atypia (P = 0.05). CONCLUSIONS:FasL expression is commonly observed not only in cancer but also in highly dysplastic tissue. These observations suggest that FasL expression may be an important event in the transformation process leading to adenocarcinoma.
Authors: Jan J Koornstra; Steven de Jong; Wietske Boersma-van Eck; Nynke Zwart; Harry Hollema; Elisabeth G E de Vries; Jan H Kleibeuker Journal: Pathol Oncol Res Date: 2009-09 Impact factor: 3.201